EP Patent

EP1677812A2 — Treating or preventing restless legs syndrome using prodrugs of gaba analogs

Assigned to XenoPort Inc · Expires 2006-07-12 · 20y expired

What this patent protects

Disclosed herein are methods of using prodrugs of gamma aminobutyric acid (GABA) analogs and pharmaceutical compositions thereof to treat or prevent restless legs syndrome in humans, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating or preventing rest…

USPTO Abstract

Disclosed herein are methods of using prodrugs of gamma aminobutyric acid (GABA) analogs and pharmaceutical compositions thereof to treat or prevent restless legs syndrome in humans, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating or preventing restless legs syndrome.

Drugs covered by this patent

Patent Metadata

Patent number
EP1677812A2
Jurisdiction
EP
Classification
—
Expires
2006-07-12
Drug substance claim
No
Drug product claim
No
Assignee
XenoPort Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.